Literature DB >> 24222091

Bile acid-mediated control of liver triglycerides.

Claudia Fuchs1, Thierry Claudel, Michael Trauner.   

Abstract

Bile acids (BAs) are steroidal molecules generated in the liver by cholesterol oxidation. Beside their well-established role in lipid absorption and cholesterol homeostasis, they function as signaling molecules and activate dedicated BA receptors such as the farnesoid X receptor (FXR) and the G-protein coupled receptor TGR5. Through activation of downstream signaling pathways of these key receptors, BAs regulate not only their own synthesis and enterohepatic circulation, but also impact on hepatic lipid, glucose, and energy homeostasis. Therefore, BA-regulated signaling pathways have emerged as attractive targets for understanding the regulation of hepatic triglyceride metabolism in health and disease and treating fatty liver disease and associated metabolic disorders. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24222091     DOI: 10.1055/s-0033-1358520

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  21 in total

Review 1.  Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?

Authors:  Rohit Kohli; Andriy Myronovych; Brandon K Tan; Rosa-Maria Salazar-Gonzalez; Lili Miles; Wujuan Zhang; Melissa Oehrle; Darleen A Sandoval; Karen K Ryan; Randy J Seeley; Kenneth D R Setchell
Journal:  Dig Dis       Date:  2015-05-27       Impact factor: 2.404

Review 2.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.

Authors:  Junli Ma; Qihang Zhou; Houkai Li
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

3.  Gut microbiota, fatty liver disease, and hepatocellular carcinoma.

Authors:  Huikuan Chu; Brandon Williams; Bernd Schnabl
Journal:  Liver Res       Date:  2018-02-21

Review 4.  FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.

Authors:  Rotonya M Carr; Andrea E Reid
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

5.  Sphingosine-1-phosphate receptor 2: a novel bile acid receptor and regulator of hepatic lipid metabolism?

Authors:  John Y L Chiang
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

6.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

Authors:  Changtao Jiang; Cen Xie; Fei Li; Limin Zhang; Robert G Nichols; Kristopher W Krausz; Jingwei Cai; Yunpeng Qi; Zhong-Ze Fang; Shogo Takahashi; Naoki Tanaka; Dhimant Desai; Shantu G Amin; Istvan Albert; Andrew D Patterson; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

Review 7.  A review on the effect of gut microbiota on metabolic diseases.

Authors:  Qiwei Shi; Lingli Dai; Qi Zhao; Xian Zhang
Journal:  Arch Microbiol       Date:  2022-02-23       Impact factor: 2.552

8.  Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.

Authors:  Anuradha Rao; Astrid Kosters; Jamie E Mells; Wujuan Zhang; Kenneth D R Setchell; Angelica M Amanso; Grace M Wynn; Tianlei Xu; Brad T Keller; Hong Yin; Sophia Banton; Dean P Jones; Hao Wu; Paul A Dawson; Saul J Karpen
Journal:  Sci Transl Med       Date:  2016-09-21       Impact factor: 17.956

9.  Fibroblast growth factor 21 correlates with weight loss after vertical sleeve gastrectomy in adolescents.

Authors:  Farooq H Khan; Lindsey Shaw; Wujuan Zhang; Rosa Maria Salazar Gonzalez; Sarah Mowery; Melissa Oehrle; Xueheng Zhao; Todd Jenkins; Kenneth D R Setchell; Thomas H Inge; Rohit Kohli
Journal:  Obesity (Silver Spring)       Date:  2016-09-12       Impact factor: 5.002

10.  The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice.

Authors:  Andriy Myronovych; Rosa-Maria Salazar-Gonzalez; Karen K Ryan; Lili Miles; Wujuan Zhang; Pinky Jha; Li Wang; Kenneth D R Setchell; Randy J Seeley; Rohit Kohli
Journal:  Obesity (Silver Spring)       Date:  2014-11       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.